X
BMY icon

Xponance’s Bristol-Myers Squibb BMY Stock Holding History

Xponance’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6M Sell
444,025
-32,517
-7% -$1.87M 0.16% 96
2026
Q1 		$28.9M Buy
476,542
+51,882
+12% +$3.02M 0.21% 76
2025
Q4 		$22.9M Buy
424,660
+18,751
+5% +$902K 0.17% 90
2025
Q3 		$18.3M Sell
405,909
-5,074
-1% -$237K 0.15% 107
2025
Q2 		$19M Buy
410,983
+47,004
+13% +$2.31M 0.16% 102
2025
Q1 		$22.2M Buy
363,979
+30,040
+9% +$1.75M 0.21% 76
2024
Q4 		$18.9M Buy
333,939
+11,370
+4% +$635K 0.17% 93
2024
Q3 		$16.7M Buy
322,569
+5,188
+2% +$243K 0.16% 99
2024
Q2 		$13.2M Buy
317,381
+25,543
+9% +$1.14M 0.13% 121
2024
Q1 		$15.8M Buy
291,838
+14,369
+5% +$732K 0.17% 110
2023
Q4 		$14.2M Buy
277,469
+20,030
+8% +$1.05M 0.17% 103
2023
Q3 		$14.9M Buy
257,439
+3,231
+1% +$198K 0.2% 84
2023
Q2 		$16.3M Sell
254,208
-4,816
-2% -$323K 0.22% 79
2023
Q1 		$18M Buy
259,024
+5,329
+2% +$376K 0.26% 71
2022
Q4 		$18.3M Buy
253,695
+34,161
+16% +$2.58M 0.3% 68
2022
Q3 		$15.6M Buy
219,534
+47,993
+28% +$3.48M 0.3% 59
2022
Q2 		$13.2M Buy
171,541
+25,261
+17% +$1.92M 0.27% 69
2022
Q1 		$10.7M Buy
146,280
+1,898
+1% +$127K 0.18% 92
2021
Q4 		$9M Sell
144,382
-26,888
-16% -$1.58M 0.14% 127
2021
Q3 		$10.1M Sell
171,270
-11,563
-6% -$761K 0.19% 92
2021
Q2 		$12.2M Sell
182,833
-78,458
-30% -$5.12M 0.22% 79
2021
Q1 		$16.5M Sell
261,291
-2,186
-0.8% -$136K 0.35% 55
2020
Q4 		$16.3M Buy
263,477
+3,201
+1% +$197K 0.36% 52
2020
Q3 		$15.7M Sell
260,276
-17,773
-6% -$1.07M 0.39% 51
2020
Q2 		$16.3M Buy
+278,049
New +$16.6M 0.42% 48

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Xponance's BMY Position: Q2 2026 in Review

Xponance reduced its Bristol-Myers Squibb (BMY) stake by 6.8% in Q2 2026, selling an estimated $1.87M and leaving 444,025 shares worth $25.6M. The position accounts for 0.16% of the portfolio, ranked #96.

Xponance first reported a position in BMY in Q2 2020 and has held it in 25 quarters since. The position peaked at $28.9M in Q1 2026. 2,511 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Xponance held 444,025 shares of Bristol-Myers Squibb worth $25.6M as of Q2 2026.
  • Xponance sold 32,517 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.87M.
  • Bristol-Myers Squibb made up 0.16% of Xponance's portfolio in Q2 2026, its #96 holding.
  • Xponance first reported a position in Bristol-Myers Squibb in Q2 2020 and has held it in 25 quarters since.
  • Xponance's Bristol-Myers Squibb position peaked at $28.9M in Q1 2026.
  • 2,511 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.